MiR-133a Acts As a Tumor Suppressor in Lung Cancer Progression by Regulating the LASP1 and TGF-β/Smad3 Signaling Pathway

Overview

Journal Thorac Cancer

Specialties Oncology
Pulmonary Medicine

Date 2020 Oct 19

PMID 33074595

Citations 9

Authors

Yuyao Shen

Yan Yang

Yahua Li

Affiliations

Soon will be listed here.

Abstract

Background: MiR-133a has been confirmed to be involved in the development of multiple cancers including non-small cell lung cancer (NSCLC). However, the precise molecular mechanism has not yet been fully elucidated. The purpose of this study was to investigate the functional role and underlying mechanism of miR-133a in the progression of NSCLC.

Methods: Quantitative real-time PCR (qRT-PCR) was performed to measure miR-133a and LASP1 expression in NSCLC tissues and cells. 3-(4, 5-dimethyl-2-thiazolyl)-2, 5-diphenyl-2H-tetrazolium bromide (MTT) assay was used to detect cell viability. The protein levels were measured by western blot. The tumor growth was measured by xenograft tumor formation assay.

Results: miR-133a was significantly decreased while LASP1 was increased in NSCLC tissues and cells compared with control groups. Moreover, overexpression of miR-133a suppressed cell viability, whereas miR-133a knockdown enhanced the viability of A549 cells. More importantly, LASP1 was verified as a direct target of miR-133a. Moreover, overexpression of miR-133a inhibited the epithelial-mesenchymal transition (EMT) and TGF-β/Smad3 pathways by regulating LASP1 in vitro. In addition, miR-133a mimic suppressed tumor growth by modulating the TGF-β/Smad3 pathway in vivo.

Conclusions: In conclusion, miR-133a acted as a tumor suppressor in lung cancer progression by regulating the LASP1 and TGF-β/Smad3 signaling pathway.

Citing Articles

Despicable role of epithelial-mesenchymal transition in breast cancer metastasis: Exhibiting restorative regimens.

Famta P, Shah S, Dey B, Kumar K, Bagasariya D, Vambhurkar G Cancer Pathog Ther. 2025; 3(1):30-47.

PMID: 39872366 PMC: 11764040. DOI: 10.1016/j.cpt.2024.01.001.

Clinical value of the expression levels of tumor protein D52 and miR-133a on prognosis assessment of pancreatic cancer surgery.

Wang Z, Liu R, Meng Y, Li J Pak J Med Sci. 2024; 40(4):723-729.

PMID: 38544991 PMC: 10963991. DOI: 10.12669/pjms.40.4.8389.

Docosahexaenoic acid (DHA) impairs hypoxia-induced cellular and exosomal overexpression of immune-checkpoints and immunomodulatory molecules in different subtypes of breast cancer cells.

Maralbashi S, Aslan C, Kahroba H, Asadi M, Soltani-Zangbar M, Haghnavaz N BMC Nutr. 2024; 10(1):41.

PMID: 38439112 PMC: 10910708. DOI: 10.1186/s40795-024-00844-y.

Regulation and therapeutic potentials of microRNAs to non-small cell lung cancer.

Le M, Nguyen H, Nguyen X, Do X, Mai B, Ngoc Nguyen H Heliyon. 2023; 9(11):e22080.

PMID: 38058618 PMC: 10696070. DOI: 10.1016/j.heliyon.2023.e22080.

Dysregulated microRNAs participate in the crosstalk between colorectal cancer and atrial fibrillation.

Ding J, Cao Y, Qi C, Zong Z Hum Cell. 2023; 36(4):1336-1342.

PMID: 36964414 DOI: 10.1007/s13577-023-00899-2.

References

Hu Z, Cui Y, Zhou Y, Zhou K, Qiao X, Li C . MicroRNA-29a plays a suppressive role in non-small cell lung cancer cells via targeting LASP1. Onco Targets Ther. 2016; 9:6999-7009. PMC: 5117897. DOI: 10.2147/OTT.S116509. View

Deng H, Qianqian G, Ting J, Aimin Y . RETRACTED: miR-539 enhances chemosensitivity to cisplatin in non-small cell lung cancer by targeting DCLK1. Biomed Pharmacother. 2018; 106:1072-1081. DOI: 10.1016/j.biopha.2018.07.024. View

Park S, Yang K, Park Y, Hong E, Hong C, Park J . Identification of Epithelial-Mesenchymal Transition-related Target Genes Induced by the Mutation of Smad3 Linker Phosphorylation. J Cancer Prev. 2018; 23(1):1-9. PMC: 5886489. DOI: 10.15430/JCP.2018.23.1.1. View

Orth M, Cazes A, Butt E, Grunewald T . An update on the LIM and SH3 domain protein 1 (LASP1): a versatile structural, signaling, and biomarker protein. Oncotarget. 2015; 6(1):26-42. PMC: 4381576. DOI: 10.18632/oncotarget.3083. View

Jin Y, Chen W, Yang H, Yan Z, Lai Z, Feng J . D. Don inhibits migration and invasion of colorectal cancer cells via suppression of PI3K/AKT and TGF-β/Smad signaling pathways. Exp Ther Med. 2017; 14(6):5527-5534. PMC: 5740531. DOI: 10.3892/etm.2017.5242. View

Sun L, Guo Z, Sun J, Li J, Dong Z, Zhang Y . MiR-133a acts as an anti-oncogene in Hepatocellular carcinoma by inhibiting FOSL2 through TGF-β/Smad3 signaling pathway. Biomed Pharmacother. 2018; 107:168-176. DOI: 10.1016/j.biopha.2018.07.151. View

Weber D, Amar L, Godde D, Prinz C . Extensive screening of microRNA populations identifies hsa-miR-375 and hsa-miR-133a-3p as selective markers for human rectal and colon cancer. Oncotarget. 2018; 9(43):27256-27267. PMC: 6007480. DOI: 10.18632/oncotarget.25535. View

Zhong C, Chen Y, Tao B, Peng L, Peng T, Yang X . LIM and SH3 protein 1 regulates cell growth and chemosensitivity of human glioblastoma via the PI3K/AKT pathway. BMC Cancer. 2018; 18(1):722. PMC: 6035445. DOI: 10.1186/s12885-018-4649-2. View

Zheng W, Zhao J, Tao Y, Guo M, Ya Z, Chen C . MicroRNA-21: A promising biomarker for the prognosis and diagnosis of non-small cell lung cancer. Oncol Lett. 2018; 16(3):2777-2782. PMC: 6096285. DOI: 10.3892/ol.2018.8972. View

10.

Zheng J, Wang F, Lu S, Wang X . LASP-1, regulated by miR-203, promotes tumor proliferation and aggressiveness in human non-small cell lung cancer. Exp Mol Pathol. 2015; 100(1):116-24. DOI: 10.1016/j.yexmp.2015.11.031. View

11.

Yang J, Bian L, Hou J, Wang H . MiR-550a-3p promotes non-small cell lung cancer cell proliferation and metastasis through down-regulating TIMP2. Eur Rev Med Pharmacol Sci. 2018; 22(13):4156-4165. DOI: 10.26355/eurrev_201807_15408. View

12.

Liao H, Pan Y, Pan Y, Shen J, Qi Q, Zhong L . MicroRNA‑874 is downregulated in cervical cancer and inhibits cancer progression by directly targeting ETS1. Oncol Rep. 2018; 40(4):2389-2398. DOI: 10.3892/or.2018.6624. View

13.

Jiang W, Wei K, Pan C, Li H, Cao J, Han X . MicroRNA-1258 suppresses tumour progression via GRB2/Ras/Erk pathway in non-small-cell lung cancer. Cell Prolif. 2018; 51(6):e12502. PMC: 6528891. DOI: 10.1111/cpr.12502. View

14.

Goldstraw P . Updated staging system for lung cancer. Surg Oncol Clin N Am. 2011; 20(4):655-66. DOI: 10.1016/j.soc.2011.07.005. View

15.

Jiang X, Dai B, Feng L . miR-543 promoted the cell proliferation and invasion of nasopharyngeal carcinoma by targeting the JAM-A. Hum Cell. 2019; 32(4):477-486. DOI: 10.1007/s13577-019-00274-0. View

16.

Tomasetto C, Regnier C, Moog-Lutz C, Mattei M, Chenard M, Lidereau R . Identification of four novel human genes amplified and overexpressed in breast carcinoma and localized to the q11-q21.3 region of chromosome 17. Genomics. 1995; 28(3):367-76. DOI: 10.1006/geno.1995.1163. View

17.

Wang Y, Li J, Chen H, Mo Y, Ye H, Luo Y . Down-regulation of miR-133a as a poor prognosticator in non-small cell lung cancer. Gene. 2016; 591(2):333-7. DOI: 10.1016/j.gene.2016.06.001. View

18.

Travis W . The 2015 WHO classification of lung tumors. Pathologe. 2014; 35 Suppl 2:188. DOI: 10.1007/s00292-014-1974-3. View

19.

Fahrmann J, Grapov D, Phinney B, Stroble C, DeFelice B, Rom W . Proteomic profiling of lung adenocarcinoma indicates heightened DNA repair, antioxidant mechanisms and identifies LASP1 as a potential negative predictor of survival. Clin Proteomics. 2016; 13:31. PMC: 5084393. DOI: 10.1186/s12014-016-9132-y. View

20.

Su W, Hong L, Xu X, Huang S, Herpai D, Li L . miR-30 disrupts senescence and promotes cancer by targeting both p16 and DNA damage pathways. Oncogene. 2018; 37(42):5618-5632. PMC: 6195819. DOI: 10.1038/s41388-018-0358-1. View